Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AGN 203818 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 3 mg |
| 2 | EXPERIMENTAL | 20 mg |
| 3 | EXPERIMENTAL | 60 mg |
| 4 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| AGN 203818 | DRUG | 3 mg Capsule twice daily for 4 weeks |
| placebo capsule | DRUG | Capsule twice daily for 4 weeks |
Inclusion Criteria: * Diagnosis of diabetic peripheral neuropathy * Moderate to severe neuropathic pain Exclusion Criteria: * Any other uncontrolled disease * Pregnant or nursing females
AGN 203818 is an investigational small molecule being developed for the treatment of painful diabetic neuropathy, a type of nerve damage caused by diabetes that leads to pain, typically in the legs and feet. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
AGN 203818 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV. The drug is an investigational small molecule in Phase 2 clinical development for the treatment of painful diabetic neuropathy.
AGN 203818 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities such as the U.S. Food and Drug Administration. The drug is being studied for the treatment of painful diabetic neuropathy.
AGN 203818 has one completed clinical trial, identified as NCT00381719, titled "Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy." This Phase 2 study enrolled 330 participants in the United States and was randomized, double-blind, and placebo-controlled.
AGN 203818 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for the treatment of painful diabetic neuropathy. The drug has completed one clinical trial, but it has not yet received regulatory approval for any use.